Cassava Sciences(NASDAQ) SAVA

Market Cap$43.50M

Since IPO (2000)-99%

5 Year-99%

1 Year-63%

1 Month-26%

$0.88

-1.72%

-0.02Today

Cassava Sciences last closing stock price
Metric	Price	Date
Last close	USD 0.88	2026-07-28

Cassava Sciences stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-12.39%	USD 1.01	2026-07-21
1 month	-26.26%	USD 1.20	2026-06-26
3 month	-38.55%	USD 1.44	2026-04-29
Year to date	-55.31%	USD 1.98	2025-12-31
1 year	-62.82%	USD 2.38	2025-07-28
3 year	-95.78%	USD 20.98	2023-07-28
5 year	-99.14%	USD 103.35	2021-07-29
Since inception	-98.99%	USD 89.24	2000-07-14

Cassava Sciences Financials at a Glance

Market Cap

$43.50M

Revenue (TTM)

$0.00

Net Income (TTM)

-$77.90M

EPS (TTM)

-$1.61

P/E Ratio

-0.56

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Price

$0.88

Volume

165,739

Open

$0.92

Price

$0.88

Volume

165,739

Open

$0.92

Previous Close

$0.88

Daily Range

$0.88 - $0.95

52-Week Range

$0.88 - $4.98

Estimated Earnings Date

May 7, 2026

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Price

$0.88

Volume

165,739

Open

$0.92

Previous Close

$0.88

Daily Range

$0.88 - $0.95

52-Week Range

$0.88 - $4.98

Estimated Earnings Date

May 7, 2026

SAVA News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cassava Sciences

Cassava develops drugs for brain diseases, focusing on epilepsy. Its main product aims to help people with severe seizures. The company also owns office property, leasing space to other businesses.

Brainy Business: Products and Services

Simufilam (Drug Candidate): Oral drug in early testing for epilepsy linked to Tuberous Sclerosis Complex; 0% of revenue as of Q3 2025.
SavaDx (Diagnostic Candidate): Blood test for Alzheimer’s detection; development stopped in mid-2025; 0% of revenue.
Office Property Leasing: Rents out part of its Austin, Texas office complex; lease revenue was $246,000 for six months ended June 2025.

Plot Twists: Growth and Expansion Moves

Discontinued all Alzheimer’s drug trials in 2024–2025 after unsuccessful Phase 3 results.
Shifted focus to TSC-related epilepsy in early 2025, licensing technology from Yale University in February 2025.
Ended SavaDx diagnostic program in mid-2025 to concentrate resources on epilepsy drug development.
Announced positive preclinical results for simufilam in TSC-related epilepsy in August 2025.
Plans to start clinical trials for simufilam in epilepsy in 2026.

What Makes Cassava Stand Out (Without the Hype)

Cassava targets a brain protein called filamin A, aiming to reduce seizures in rare epilepsy. The company holds exclusive global rights to its main drug for this use. It also manages a large office property, providing some rental income.

Five Things You Need to Know

Revenue was $840,000 in Q3 2025, up from $0 in Q3 2024.
Net income reached $70 million in Q3 2025, up 320.6% from Q3 2024.
Cash and equivalents were $112.4 million as of June 30, 2025.
Research and development expenses fell 66% year-over-year in Q2 2025.
Litigation reserves rose to $35.25 million by June 2025 due to legal challenges.

Bottom Line

Cassava has shifted from Alzheimer’s research to rare epilepsy, cutting costs and focusing on one main drug. The company faces legal and financial hurdles but maintains cash reserves for near-term operations.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Richard Jon Barry

Website

www.cassavasciences.com

Headquarters

Austin, TX 78731, US

SAVA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-99.85%

Return on Capital

-128.21%

Return on Assets

-71.89%

Earnings Yield

-1.79%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$43.50M

Shares Outstanding

48.31M

Volume

165.74K

Avg. Volume

384.95K

Financials (TTM)

Gross Profit

$13.42M

Operating Income

-$81.97M

EBITDA

-$84.01M

Operating Cash Flow

-$29.79M

Capital Expenditure

-$581.00K

Free Cash Flow

-$30.38M

Cash & ST Invst.

$86.57M

Total Debt

$0.00

Cassava Sciences Performance Analysis

Cassava Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Cassava Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Cassava Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.90	130.8%
2023	2023-12-31	USD -2.32	22.2%
2024	2024-12-31	USD -1.46	-36.9%
2025	2025-12-31	USD -1.88	28.8%

Cassava Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-91.7%
Q3	2025-09-30	76.1%
Q4	2025-12-31	-18.2%
Q1	2026-03-31	19.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$243.00K

+98.2%

Gross Margin

0.00%

N/A

Market Cap

$43.50M

N/A

Market Cap/Employee

$1.45M

N/A

Employees

N/A

Net Income

-$10.33M

+55.9%

EBITDA

-$10.93M

+48.9%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$86.57M

-26.2%

Total Debt

$0.00

N/A

Accounts Receivable

$117.00K

-86.5%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-71.89%

N/A

Return on Invested Capital

-1.20%

N/A

Free Cash Flow

-$8.88M

+21.7%

Operating Cash Flow

-$8.88M

+21.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

RANIRani Therapeutics Holdings, Inc.

RANIRani Therapeutics Holdings, Inc.$0.82+1.14%

CRDFCardiff Oncology, Inc.

CRDFCardiff Oncology, Inc.$0.82-2.14%

ELTXElicio Therapeutics, Inc.

ELTXElicio Therapeutics, Inc.$2.95-1.67%

MISTMilestone Pharmaceuticals Inc.

MISTMilestone Pharmaceuticals Inc.$1.07-5.31%

PEPGPepGen Inc.

PEPGPepGen Inc.$1.83-3.68%

MOLNMolecular Partners AG

MOLNMolecular Partners AG$3.83-4.36%

NKTXNkarta, Inc.

NKTXNkarta, Inc.$2.22-1.77%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.22-0.01%

NOKNokia

NOKNokia$8.93-0.03%

JBLUJetBlue Airways

JBLUJetBlue Airways$6.00+0.10%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.15-0.01%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$116.41+0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$61.56-0.03%

MARAMara Holdings

MARAMara Holdings$11.38-0.03%

Questions About SAVA

What is the current price of Cassava Sciences?

Cassava Sciences is trading at $0.88 per share.

What is the 52-week range for Cassava Sciences?

Over the past 52 weeks, Cassava Sciences has traded between $0.88 and $4.98.

How much debt does Cassava Sciences have?

As of the most recent reporting period, Cassava Sciences reported total debt of $0.00.

How much cash does Cassava Sciences have on hand?

Cassava Sciences reported $86.57M in cash and cash equivalents in its most recent financial results.

What is Cassava Sciences’s dividend yield?

Cassava Sciences does not currently have a dividend yield.

Cassava Sciences(NASDAQ) SAVA

Cassava Sciences Financials at a Glance

SAVA News

Cassava Sciences Posts Q2 Loss on Pivot

Why Cassava Sciences Stock Dived by Almost 11% Today

Why Cassava Sciences Stock Is Skyrocketing Today

Why Cassava Sciences Stock Is Sinking Today

Is There Any Hope for Cassava Sciences Stock?

Why Cassava Sciences Stock Zoomed 21% Higher This Week

Why Cassava Sciences Stock Soared Today

1 Big Red Flag to Fear When a Stock Is Down

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cassava Sciences

Brainy Business: Products and Services

Plot Twists: Growth and Expansion Moves

What Makes Cassava Stand Out (Without the Hype)

Five Things You Need to Know

Bottom Line

SAVA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cassava Sciences Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SAVA

What is the current price of Cassava Sciences?

What is the 52-week range for Cassava Sciences?

How much debt does Cassava Sciences have?

How much cash does Cassava Sciences have on hand?

What is Cassava Sciences’s dividend yield?

Premium Investing Services